Assuring Radiation Protection (U18) Clinical Trial Not Allowed

FDA is announcing its intention to accept and consider a renewal application for a cooperative agreement, with the availability of approximately $105,000 in total fiscal year (FY) 2023 funds, in support of coordination of Federal and State actions to assure radiation protection of the American public. The recipient will also plan and facilitate an annual meeting, and develop and offer educational activities to demonstrate mutually beneficial techniques, procedures, and systems relevant to the mission of assuring radiation protection. The recipient will establish committees to address, evaluate, and offer solutions for a wide range of radiation health and protection issues. The cooperative agreement described by this notice is authorized under section 532 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ii), which provides FDA authority to establish and carry out an electronic product radiation control program.